Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$32.0B
377M shares
52-week range
$54.11 – $92.59
85% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
P/S (TTM)
6.9
EV / FCF (TTM)
24.4
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
www.dexcom.comNo one on the platform currently holds DXCM.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,582,996 | $99.4M |
| Bridgewater Associatesas of 2026-03-31 | 139,687 | $8.8M |
| Execution date | Ratio |
|---|---|
| 2022-06-13 | 4-for-1 |
No one on the platform has traded DXCM yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 21.8% | 12.3% | — | — | — | |
| Rev. Growth % | 15.6% | 19.3% | ||||
| Profit Margin % | 17.9% | 13.6% | 6.9% | |||
| Free Cash Flow Margin % | 23.1% | 13.1% | 9.8% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +8.1% on the P/E track.
At today's price, your expected annual return is +13.6% on the P/E track.
At today's price, your expected annual return is +18.3% on the P/E track.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $5.2B | +12.4% | $2.67 | $2.48–$2.73 | 32.6× | 15 |
| 2027 | $5.8B | +10.8% | $3.12 | $2.87–$3.33 | 27.8× | 16 |
| 2028 | $6.5B | +11.3% | $3.72 | $2.91–$4.01 | 23.4× | 7 |
| 2029 | $7.2B | +11.6% | $4.33 | $4.23–$4.43 | 20.1× | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $0.61 | $0.70 | +14.6% |
| 2026-04-30 | $0.47 | $0.56 | +20.3% |
| 2026-02-12 | $0.65 | $0.68 | +4.6% |
| 2025-10-30 | $0.58 | $0.61 | +5.9% |
| 2025-07-30 | $0.44 | $0.48 | +8.2% |
| 2025-05-01 | $0.33 | $0.32 | -2.2% |
| 2025-02-13 | $0.48 | $0.45 | -6.1% |
| 2024-10-24 | $0.44 |
| $0.45 |
| +2.3% |
| $9.6B |
| — |
| SNNSmith & Nephew plc | $28.04 | -1.29% | $11.8B | — |
| STESTERIS plc | $212.62 | -0.49% | $20.7B | — |
Source: Financial Modeling Prep · peers by sector/industry
$SANA $ELDN $DXCM $PODD $TNDM It appears it is safe to assume Endo Axiom's Smart Oral insulin is now in human(s). Please Jesus let this work. This will ineffably transform the lives for us T1D's. Sana with sc451 is still on the horizon with Ph 1/2 to begin this year, IMHO the best potential option. Tego + Cadaveric islets is here RIGHT NOW with 12 out of 12 people (functionally) cured. T1D your days are numbered bitch. https://www.sydney.edu.au/news-opinion/news/2026/09/10/oral-insulin-drug-achieves-a-critical-milestone--.html
View on StockTwits ↗
$SANA $ELDN $DXCM $PODD $TNDM Today is scheduled to be the first person ever dosed with Endo Axium Smart Oral Insulin. This could potentially radically change the lives for us T1D's, with even better stuff on the horizon. 🙏🏻🤞
View on StockTwits ↗
$DXCM Out with $3,900 profit. 💋 Not too shabby for less than 48 hours. Shorted it first, then covered the short once I had my puts options purchased. Already l👀king to reenter puts on any gap ups.
View on StockTwits ↗
$DXCM one hour has nice hammer candle expecting g something big incoming towards downside
View on StockTwits ↗$DXCM it’s going to be volatile few months best time to get in puts
View on StockTwits ↗$DXCM I may, or may not have, taken a semi-aggressive bearish position in this stock today. 💋 Stock is a wee bit out ahead of its skis, imo. But I did love it in the $50's.
View on StockTwits ↗$DXCM Stock only $2.00 off 52-wk highs as we enter Sep, historically the absolute worst month for this stock. Only a 10% win rate in Sep over the past decade, and not a green one since 2021. For these reasons, I'm bearish at this moment in time.
View on StockTwits ↗
$DXCM Solid company Not cheap Negative float though and making money with that fact. 👍🏼
View on StockTwits ↗
$DXCM Potential!! This could be great! Start looking inot the acquisition of Modular Medical MODD. Their insulin patch pump looks very promising 🔥🔥🚀🚀
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.